Artur Katz

7PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsGene expression (incl. microarray and other genome-wide approaches)Major global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 01, 2026
Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study.

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Sep 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.

Yoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen

|May 27, 2022
Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma.

Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo

|Jul 16, 2021
Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome.

Renata Lazari Sandoval, Cibele Masotti, Mariana Petaccia de Macedo

|Feb 13, 2021
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni

Pageof 2

Frequent Collaborators

5 joint publications

Maurício Fernando Silva Almeida Ribeiro

2 joint publications

Anamaria Aranha Camargo

2 joint publications

Andrea Kazumi Shimada

2 joint publications

Rodrigo Saddi